No Data
The China-based clinical trial of the Claudin18.2 CAR-T therapy ShuRuiJi Oulansi injection, the world's first of its kind developed by Keji Pharmaceutical, for confirmed stage II gastric cancer patients has completed enrollment.
Shanghai, August 19, 2024 / PRNewswire / - Kojie Pharmaceutical (stock code: 2171.HK), an innovative CAR-T cell therapy company that focuses on treating hematological malignancies and solid tumors, announced that CT041 (a self-targeting Claudin18.2 CAR-T cell candidate product) - shrudge base Orlans injection (development code: CT041), a Phase II clinical trial for advanced gastric/esophageal gastric junction adenocarcinoma in China, has completed enrollment and randomization of all subjects according to the clinical protocol. The trial is an open-label study conducted in China.
Kaiser Pharmaceuticals-B (02171.HK): Clinical Phase II trials of Surojelone Injection, a China-confirmed drug, have completed enrollment.
KCH August 19th | Koji Pharmaceutical-B (02171.HK) issued an announcement stating that the IIa clinical trial of Shuruijiaoluensai injection (research and development code: CT041, a targeting Claudin18.2 autologous CAR-T cell candidate product) being conducted in China has completed enrollment and randomization according to the clinical plan. The trial is an open-label, multicenter, randomized controlled clinical trial conducted in China, aimed at evaluating Shuruijiaoluensai injection for the treatment of advanced gastric/esophageal junction adenocarcinoma with positive expression of Claudin18.2 and a history of failure of at least 2 treatments.
Kojie Pharmacy-B (02171.HK) plans to hold a board of directors meeting on August 28 to approve its interim performance.
Kaiji Pharmaceutical-B (02171.HK) announced on August 15th that the board of directors meeting will be held on Wednesday, August 28th, 2024, to consider and approve the group's interim performance for the six months ending June 30th, 2024, as well as to handle other matters.
CARSGEN-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
On June 28, Keji Pharmaceutical -B (02171.HK) spent HKD 720,000 to repurchase 150,000 shares.
On June 28th, Keji Pharmaceutical -B (02171.HK) announced that it had spent HKD 720,000 to repurchase 150,000 shares.
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% DropNo Data
